For laboratory & research use only. Not for human consumption.
Cognitive & Nootropic

Semax vs Selank

Semax and Selank — or Selank vs Semax, depending on which order you're comparing them in — are the two best-known peptides to come out of Nikolai Myasoedov's Moscow research program, built using the same stabilization technique but starting from two completely different parent molecules.

At a Glance

SemaxSelank
CategoryCognitive & NootropicCognitive & Nootropic
Molecular classHeptapeptide, derived from ACTH(4-7)Heptapeptide, derived from tuftsin
Discovery timeline1982, Nikolai Myasoedov & Igor Ashmarin1990s, Myasoedov's team with the V.V. Zakusov Institute
Stabilization methodPro-Gly-Pro tail added to ACTH(4-7)Pro-Gly-Pro tail added to tuftsin
Original parent activityHormonal (adrenocorticotropic hormone fragment)Immunomodulatory (immune-system peptide)
Primary mechanism studiedNeuroprotection, BDNF expressionAnxiolytic-like activity, neuropeptide behavior research
Human trial evidenceGusev et al., 2018: 110 ischemic stroke patientsZozulya et al., 2008: 62 patients, compared with medazepam
Status in RussiaRegistered pharmaceutical since 1994Prescription pharmaceutical since 2009
KYIN purity (current batch)99.011%99.127%
KYIN priceRM 200 (S$60), 10mgRM 200 (S$60), 10mg

How They Differ

Semax was created in 1982 by fusing the stabilizing Pro-Gly-Pro tripeptide onto ACTH(4-7) — a fragment of adrenocorticotropic hormone already known to have nootropic effects independent of ACTH's hormonal role, but which broke down too quickly in the body to be useful on its own. See its full discovery history.

Selank uses the exact same Pro-Gly-Pro stabilization trick, but applied to a completely different starting molecule: tuftsin, a naturally occurring immune-system peptide. Stabilizing tuftsin didn't just extend its half-life — it also revealed a second, unexpected property: pronounced effects in anxiolytic and neuromodulatory research models. See its full discovery history.

Why They're Often Studied Together

Semax and Selank are frequently discussed together because they share both a research lineage and an engineering technique, even though they started from unrelated parent molecules (a hormone fragment versus an immune peptide) and are studied for different primary effects — neuroprotective/cognitive research for Semax, anxiolytic research for Selank.

Mechanisms Side by Side

Both peptides reach similar neurotrophic territory, raising brain-derived neurotrophic factor (BDNF), but from different starting points and with different emphasis. Semax's research profile centers on BDNF expression in the hippocampus, modulation of dopamine and serotonin systems, and neuroprotective effects in ischemia models, without the cortisol-stimulating activity of its parent hormone ACTH. Selank's centers on effects on monoamine turnover and GABAergic signaling alongside BDNF; in research models it has not shown the sedation or dependence liability associated with benzodiazepines, which drives much of the interest in it. See the Semax and Selank mechanism pages.

What the Human Evidence Shows

Each has one notable published human trial. For Semax, Gusev et al. (2018) studied 110 ischemic stroke patients and found increased plasma BDNF and faster functional recovery. For Selank, Zozulya et al. (2008) compared it with the benzodiazepine medazepam in 62 patients with generalized anxiety disorder or neurasthenia and found comparable anxiolytic effects, plus antiasthenic effects the benzodiazepine did not show. Both trials come from Russian-language clinical literature and neither has been replicated in a Western trial, so they are real human evidence but outside the FDA approval pathway.

Regulatory Status

Both are approved pharmaceuticals in Russia: Semax since 1994 and Selank since 2009. Neither is FDA-approved. In July 2026 an FDA advisory committee recommended Semax for the 503A compounding bulks list, a non-binding vote that is not drug approval; see what that update means. KYIN Peptides sells both strictly for laboratory research use.

Handling and Storage

Because both are heptapeptides stabilized with the same Pro-Gly-Pro tail and supplied as lyophilized powder, their handling is comparable. See our storage guide and reconstitution guide for general considerations, and the Semax and Selank certificate guides for what each batch's testing reports.

Which One Is Right for a Given Study?

There isn't a straightforward "better" between Semax and Selank — the two are studied for different primary mechanisms, so the choice generally comes down to what a protocol is investigating. Semax's research focus is neuroprotective and cognitive, tied to its ACTH(4-7) origin, while Selank's is anxiolytic and neuromodulatory, tied to its tuftsin origin. Some study designs reference both in the same protocol given their shared stabilization method and comparable handling.

⚠
Research Use Only Notice This page compares Semax and Selank for educational and research context only. It is not a claim about current regulatory approval, safety, or legal status in any market. Both peptides are sold strictly for laboratory research use by qualified professionals — not for human or animal use, and not intended for diagnostic, therapeutic, or consumption purposes.
FAQ

Semax vs Selank questions

Why are Semax and Selank so often compared?

Because they come from the same Moscow research program and use the identical Pro-Gly-Pro stabilization technique, despite being built from unrelated starting molecules and studied for different primary effects — Semax for neuroprotective and cognitive research, Selank for anxiolytic research.

Does this comparison mean Semax and Selank are approved for a particular use?

No. This page compares Semax and Selank for educational and research context only. Both are sold strictly for laboratory research use and are not evaluated or approved for human or animal use.

Which is better, Semax or Selank?

Neither is strictly "better" — they're studied for different primary mechanisms, so the right choice depends on what a given protocol is investigating: neuroprotective/cognitive research for Semax versus anxiolytic research for Selank.

What are Semax and Selank used for in research?

Semax is primarily studied for neuroprotective and cognitive research applications, tied to its ACTH(4-7) origin. Selank is primarily studied for anxiolytic and neuromodulatory research applications, tied to its tuftsin origin.

What is the difference between Semax and Selank?

Semax is built from ACTH(4-7), a hormone fragment, and is studied mainly for neuroprotective and cognitive effects. Selank is built from tuftsin, an immune peptide, and is studied mainly for anxiolytic-like effects. Both use the same Pro-Gly-Pro stabilization and both raise BDNF in research models.

Are Semax and Selank approved anywhere?

Both are approved pharmaceuticals in Russia, Semax since 1994 and Selank since 2009. Neither is FDA-approved; a July 2026 FDA advisory vote on Semax for the 503A compounding list was non-binding and is not drug approval.

Is there human trial data for Semax and Selank?

Yes, from Russian-language literature: Gusev et al. (2018) studied Semax in 110 ischemic stroke patients, and Zozulya et al. (2008) compared Selank with medazepam in 62 patients with anxiety disorders. Neither has been replicated in a Western trial.

Looking for specs and pricing?

View purity, available sizes, and pricing for both.